Bellicum Pharmaceuticals Inc (BLCM)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Richard A. Fair
Employees:
7
2130 WEST HOLCOMBE BOULEVARD, SUITE 800, HOUSTON, TX 77030
(832) 384-1100

Bellicum Pharmaceuticals, Inc. focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the. treatment of solid tumors expressing the prostate stem cell antigen.

Data derived from most recent annual or quarterly report
Market Cap 5.907 Million Shares Outstanding9.496 Million Avg 30-day Volume 5.948 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.02
Price to Revenue6.7834 Debt to Equity0.0 EBITDA-25.503 Million
Price to Book Value0.0 Operating Margin-1979.1333000000002 Enterprise Value17.337 Million
Current Ratio3.847 EPS Growth-5.833 Quick Ratio3.439
1 Yr BETA 0.9394 52-week High/Low 1.55 / 0.23 Profit Margin-1698.4667
Operating Cash Flow Growth-21.9254 Free Cash Flow to Firm (FCFF) TTM -23.728 Million Free Cash Flow to Equity (FCFE) TTM-20.8 Million
Altman Z-Score-49.9378
View SEC Filings from BLCM instead.

View recent insider trading info

Bellicum Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding BLCM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BLCM

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3: filed on 2023-05-05 by BAKER JULIAN
  • 4/A: filed on 2023-01-20 by HUBER REID M
  • 4: filed on 2023-01-05 by DALY JAMES M
  • 4: filed on 2023-01-05 by DAVIS STEPHEN
  • 4: filed on 2023-01-05 by HUBER REID M
  • 4: filed on 2023-01-05 by STONEHOUSE JON P
  • 4: filed on 2023-01-05 by KLIMOVSKY JUDITH V
  • 4: filed on 2022-09-02 by KLIMOVSKY JUDITH V
  • 4: filed on 2022-09-02 by DAVIS STEPHEN
  • 4: filed on 2022-09-02 by DALY JAMES M

    • Events (8k)

  • 8-K: filed on 2023-11-22:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-29:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-18:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-06-02:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-05-30:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2023-04-11:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2022-12-12:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-07:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-11-10:
    Item 2.02: Results of Operations and Financial Condition
  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BAKER BROS. ADVISORS LP

    BAKER JULIAN

    BAKER FELIX

    BAKER BROS. ADVISORS (GP) LLC

    • 10% Owner
    		 16,583,316 2023-11-22 2

    DAVIS STEPHEN

    • Director
    		 136,854 2023-01-03 1

    STONEHOUSE JON P

    • Director
    		 204,086 2023-01-03 1

    DALY JAMES M

    • Director
    		 109,873 2023-01-03 1

    HUBER REID M

    • Director
    		 153,179 2023-01-03 2

    KLIMOVSKY JUDITH V

    • Director
    		 110,098 2023-01-03 1

    FAIR RICHARD A. PRESIDENT AND CEO

    • Officer
    • Director
    		 400,000 2022-08-15 0

    SCRIPTURE CHARITY CHIEF DEVELOPMENT OFFICER

    • Officer
    		 250,000 2022-08-15 0

    BROWN JAMES F

    • Director
    		 0 2022-01-04 0

    GRASS CHARLES S. PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 0 2021-05-11 0

    STRAUSS DAVID ERIC SR DIRECTOR, CORP CONTROLLER

    • Officer
    		 0 2020-12-15 0

    WARD SHANE SR VP AND CHIEF LEGAL SO

    • Officer
    		 1,879 2020-05-29 0

    MOKARI ATABAK CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2020-04-08 0

    SMITH ALAN K. EVP, TECHNICAL OPERATIONS

    • Officer
    		 0 2020-04-08 0

    FOSTER AARON E. SR VP, HEAD OF RESEARCH

    • Officer
    		 0 2020-04-08 0

    WILLIAMS ROSEMARY Y. VP, FINANCE & PAO

    • Officer
    		 5,756 2020-01-02 0

    WOODARD JR JOSEPH PAUL SVP CLINICAL & MEDICAL AFFAIRS

    • Officer
    		 5,467 2019-11-13 0

    NAEVE GREGORY S. CHIEF BUSINESS OFFICER

    • Officer
    		 13,746 2019-08-21 0

    HARRIGAN EDMUND

    • Director
    		 0 2019-06-13 0

    GROSSMAN WILLIAM SR. VP, CHIEF MEDICAL OFFICER

    • Officer
    		 26,874 2019-02-05 0

    SPENCER DAVID M. CHIEF TECHNOLOGY OFFICER

    • Officer
    		 0 2019-02-01 0

    MUSSO ALAN A CFO AND TREASURER

    • Officer
    		 0 2018-07-02 0

    MCGUYER FRANK B.

    • Director
    		 0 2018-06-14 0

    MOSELEY KEN SR. VP AND GENERAL COUNSEL

    • Officer
    		 3,658 2018-01-03 0

    SLAWIN KEVIN M.

    • Director
    		 0 2017-06-14 0

    FARRELL THOMAS J. PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2017-01-03 0

    MOSELEY ANNEMARIE COO/EVP CLINICAL DEVELOPMENT

    • Officer
    		 0 2017-01-03 0

    HOANG PETER L. SR. VP OF BUS. DEVELOPMENT

    • Officer
    		 0 2017-01-03 0

    SENESAC JOSEPH VP OF MANUFACTURING

    • Officer
    		 0 2015-02-24 0

    REMEDITEX VENTURES LLC

    • 10% Owner
    		 1,807,603 2014-12-23 0

    MCGUYER INVESTMENTS LTD.

    • 10% Owner
    		 2,215,398 2014-12-23 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    BAKER BROS. ADVISORS LP - > 10% Owner see footnotes

    BAKER JULIAN - > 10% Owner see footnotes

    BAKER FELIX - > 10% Owner see footnotes

    BAKER BROS. ADVISORS (GP) LLC - > 10% Owner see footnotes

    		2023-11-24 13:39:11 -0500 2023-11-22 X 174,742 $0.00 a 196,654 indirect

    BAKER BROS. ADVISORS LP - > 10% Owner see footnotes

    BAKER JULIAN - > 10% Owner see footnotes

    BAKER FELIX - > 10% Owner see footnotes

    BAKER BROS. ADVISORS (GP) LLC - > 10% Owner see footnotes

    		2023-11-24 13:39:11 -0500 2023-11-22 X 174,742 d 1,287,987 indirect

    BAKER BROS. ADVISORS LP - > 10% Owner see footnotes

    BAKER JULIAN - > 10% Owner see footnotes

    BAKER FELIX - > 10% Owner see footnotes

    BAKER BROS. ADVISORS (GP) LLC - > 10% Owner see footnotes

    		2023-11-24 13:39:11 -0500 2023-11-22 X 1,941,607 $0.00 a 2,168,818 indirect

    BAKER BROS. ADVISORS LP - > 10% Owner see footnotes

    BAKER JULIAN - > 10% Owner see footnotes

    BAKER FELIX - > 10% Owner see footnotes

    BAKER BROS. ADVISORS (GP) LLC - > 10% Owner see footnotes

    		2023-11-24 13:39:11 -0500 2023-11-22 X 1,941,607 d 14,217,844 indirect

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    BELLICUM PHARMACEUTICALS INC BLCM 2023-12-01 16:45:03 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-12-01 16:15:04 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-12-01 15:45:03 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-12-01 15:15:05 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-12-01 14:45:03 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-12-01 14:15:04 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-12-01 13:45:04 UTC -243.7358 249.0558 300000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-12-01 13:15:04 UTC -243.7358 249.0558 200000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-12-01 12:45:04 UTC -243.7358 249.0558 200000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-11-30 22:15:04 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-11-30 21:45:04 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-11-30 21:15:05 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-11-30 20:45:05 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-11-30 20:16:16 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-11-30 19:45:03 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-11-30 19:15:04 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-11-30 18:45:04 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-11-30 18:15:04 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-11-30 17:45:04 UTC -243.7358 249.0558 350000
    BELLICUM PHARMACEUTICALS INC BLCM 2023-11-30 17:15:04 UTC -243.7358 249.0558 350000

    Current Active Short Positions

    Get more info on our International short position coverage here

    Holder Issuer Net Short Position Position Date Origin

    Short Position History (International Only)

    Holder Net Short Position Position Date Origin
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 1.26% 2020-03-30 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 0.49% 2020-06-02 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 0.59% 2020-05-22 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 0.69% 2020-05-18 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 0.79% 2020-05-12 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 0.89% 2020-04-29 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 0.99% 2020-04-09 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 1.09% 2020-04-06 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 1.19% 2020-04-01 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 1.5% 2020-02-07 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 1.39% 2020-03-25 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 1.46% 2020-03-24 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 1.64% 2020-03-19 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 1.79% 2020-03-13 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 1.96% 2020-03-11 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 1.81% 2020-02-14 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 1.73% 2020-02-13 GERMANY
    Squarepoint Ops LLC Bellicum Pharmaceuticals Inc 1.6% 2020-02-11 GERMANY

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments